01 Industry overview
The traditional chinese medicine industry at a glance
China’s traditional Chinese medicine industry is estimated at RMB1,589.6 billion in 2025, with medical services accounting for most activity and the overall market forecast to expand through 2029.
- RMB1.59T[6]
- China TCM market, 2025E
- 9.3%[6]
- 2024–2029 forecast CAGR
- 103,704[7]
- TCM institutions, 2024
- 65.3%[8]
- Top five export markets, 2025
- Market size
- China’s broad traditional Chinese medicine market was estimated at RMB1,448.6 billion in 2024 and RMB1,589.6 billion in 2025E. The market definition includes TCM pharmaceuticals, TCM medical services and other segments such as diagnostic and health-monitoring devices.[6]
- Forecast & CAGR
- The market is forecast to reach RMB2,261.5 billion by 2029, implying a 9.3% CAGR from 2024 to 2029. TCM medical services are forecast to grow faster, at 10.1% annually, while TCM pharmaceuticals are projected to grow at 4.1%.[6]
- Market share & regions
- China remains the industry’s main operating base, while exports of Chinese medicinal materials and decoction pieces are concentrated in Asia. In 2025, Japan represented 24.4% of export value, South Korea 10.8%, Hong Kong 10.5%, Taiwan 10.0% and Vietnam 9.6%; together, these five markets accounted for 65.3%.[8]
- Segmentation
- In 2024, TCM medical services generated RMB1,001.6 billion, compared with RMB392.4 billion for TCM pharmaceuticals and RMB54.6 billion for other activities. The service segment therefore represented about 69.1% of the total market on the cited definition.[6]
- Trends, drivers & challenges
- Global traditional and complementary medicine revenue reached an estimated $646.3 billion in 2025, increasing 7.2% from 2024 to 2025; the Global Wellness Institute projects 9.1% annual growth through 2030. Growth drivers include demand for preventive care, chronic-condition management and wellness, while evidence, standardization and integration with conventional healthcare remain important challenges.[9][10]
- Consumer behavior & competition
- China’s TCM medical institutions recorded more than 1.8 billion visits in 2025, while the number of institutions exceeded 110,000. The scale of visits indicates strong domestic use, with competition spanning hospitals, outpatient clinics, pharmacies, wellness providers and digital services.[11]
- Regulation
- China’s State Council issued the Regulation on the Protection of Traditional Chinese Medicine Traditional Knowledge on October 23, 2026; it will take effect on January 1, 2027. The regulation covers traditional theories and methods, classic and proven formulas, cultivation and identification techniques, decoction-piece processing and traditional preparation methods.[12]
- Latest news
- In September 2026, the World Health Organization launched its Global Research Priorities and Agenda for Traditional, Complementary and Integrative Medicine 2025–2034. The agenda follows adoption of the WHO Global Traditional Medicine Strategy 2025–2034 by all 194 WHO Member States in May 2025.[10]
02 Ranking
Top 10 Companies in the Traditional Chinese Medicine Industry
The leading companies in the traditional chinese medicine industry, ranked on market impact, performance, momentum, innovation and brand popularity.
Updated November 22, 2026 · Next review December 22, 2026
Ranked by Overall score · How we score ↓
Editor's top 3 picks
Where to start, by need.
#1 Overall · #1 overall
Tsumura & Co.
JP
Ranked #1 · 9.3 · Prescription Kampo (Japanese herbal) medicines, Japan
#2 overall
Shijiazhuang Yiling Pharmaceutical
CN
Ranked #2 · 9.1 · Traditional Chinese medicines, China
#3 overall
Tonghua Dongbao Pharmaceutical Group
CN
Ranked #3 · 8.9 · TCM and insulin pharmaceuticals, China
Pick 1 is the #1 company overall. No other segment places in the top 5, so picks 2 and 3 follow rank.
Full ranking
| # | Company | Overall ↓ | Impact | Performance | Momentum | Innovation | Company snapshot |
|---|---|---|---|---|---|---|---|
| 1 | Tsumura & Co. Prescription Kampo (Japanese herbal) medicines, Japan · JP | 9.3 | 9.9 | 8.5 | 9.1 | 9.5 | |
Company snapshot · Tsumura & Co. · Data as of November 22, 2026 Holds 84.6% of Japan's prescription Kampo market and markets 129 of 148 government-approved formulations.[13]
| |||||||
| 2 | Shijiazhuang Yiling Pharmaceutical Traditional Chinese medicines, China · CN | 9.1 | 8.4 | 9.4 | 9.9 | 9.0 | |
Company snapshot · Shijiazhuang Yiling Pharmaceutical · Data as of November 22, 2026
| |||||||
| 3 | Tonghua Dongbao Pharmaceutical Group TCM and insulin pharmaceuticals, China · CN | 8.9 | 7.0 | 9.9 | 9.8 | 9.9 | |
Company snapshot · Tonghua Dongbao Pharmaceutical Group · Data as of November 22, 2026 Jilin-based pharmaceutical group with TCM product lines alongside biotech.[14]
| |||||||
| 4 | Dong-E-E-Jiao Traditional Chinese medicines, China · CN | 8.7 | 8.4 | 8.6 | 9.2 | 9.0 | |
Company snapshot · Dong-E-E-Jiao · Data as of November 22, 2026
| |||||||
| 5 | Jumpcan Pharmaceutical Group TCM respiratory and pediatric medicines, China · CN | 8.7 | 8.4 | 8.7 | 9.1 | 8.5 | |
Company snapshot · Jumpcan Pharmaceutical Group · Data as of November 22, 2026 Ranked among China's top-10 listed TCM companies by 2024 operating revenue.[15]
| |||||||
| 6 | Xiuzheng Pharmaceutical Group OTC and prescription traditional Chinese medicines, China · CN | 8.3 | 8.4 | 8.5 | 8.2 | 8.0 | |
Company snapshot · Xiuzheng Pharmaceutical Group · Data as of November 22, 2026 Ranked No.13 among China's pharmaceutical companies by 2024 industrial main-business revenue.[16]
| |||||||
| 7 | Tasly TCM and modernised herbal pharmaceuticals, China · CN | 8.2 | 8.4 | 8.0 | 7.8 | 8.3 | |
Company snapshot · Tasly · Data as of November 22, 2026 Known for TCM-based cardiovascular product Cardiotonic Pill; expanded internationally.[17]
| |||||||
| 8 | China Shineway Pharmaceutical Group Traditional Chinese medicines, China · CN | 7.8 | 8.4 | 8.2 | 7.0 | 7.4 | |
Company snapshot · China Shineway Pharmaceutical Group · Data as of November 22, 2026
| |||||||
| 9 | Kwangdong Pharmaceutical Korean traditional herbal medicines, South Korea · KR | 7.5 | 7.0 | 7.6 | 8.0 | 7.5 | |
Company snapshot · Kwangdong Pharmaceutical · Data as of November 22, 2026
| |||||||
| 10 | PuraPharm Traditional Chinese medicines and Chinese healthcare, Hong Kong · HK | 7.3 | 7.4 | 7.0 | 7.0 | 8.0 | |
Company snapshot · PuraPharm · Data as of November 22, 2026
| |||||||
How we score
- Impact (30%): scale and weight in the market (revenue, market share, employees, market position).
- Performance (20%): recent revenue growth and operating margin; an analyst assessment where a company does not publish them.
- Momentum (20%): growth trajectory and future potential.
- Innovation (15%): R&D intensity and how technologically advanced the company is.
Popularity (brand search demand, 15%) counts toward Overall but is not published as a column. Overall leaves out what is not known.
Scale Scores are shown on a 7–10 scale with one decimal; bars start at 7.0.
Cadence Recalculated when new figures are published; next review December 22, 2026.
Independence. Rankings are editorially independent. Scores, ranks, picks and the verdict follow the method above; no company can pay to change them.
Cite this ranking
APA
Samuel Norberg. (2026, November 22). Top 10 companies in the traditional chinese medicine industry. In Traditional Chinese Medicine Industry Statistics. Gitnux. https://gitnux.org/traditional-chinese-medicine-industry-statistics/#top-companies
Market share in the China astragalus medicine market
Sichuan Baili Pharmaceutical leads with 46.3%.
03 Trends & forecasts
Top 10 Traditional Chinese Medicine Industry Trends & Forecasts 2027
What is changing in the traditional chinese medicine industry, with the evidence behind each trend and a forecast for 2027.
Forecasts were generated by an AI model from the cited evidence. They are estimates, not guarantees.
01TCM market growth accelerates
High confidenceChina’s broad TCM market increased from RMB1,079.4 billion in 2019 to RMB1,448.6 billion in 2024, and is estimated at RMB1,589.6 billion in 2025. The cited industry forecast puts the market at RMB2,261.5 billion in 2029, implying a 9.3% CAGR for 2024–2029.[6]
Forecast 2027: The market is likely to reach approximately RMB1,910.1 billion in 2027, based on the cited forecast series. Growth should remain broad-based but increasingly concentrated in medical services, digital offerings and wellness-related activities.
02Medical services outpace pharmaceuticals
High confidenceTCM medical services generated RMB1,001.6 billion in 2024, compared with RMB392.4 billion for TCM pharmaceuticals. Medical services are forecast to grow at a 10.1% CAGR from 2024 to 2029, versus 4.1% for pharmaceuticals.[6]
Forecast 2027: Medical services should remain the industry’s primary growth engine in 2027, with forecast revenue of about RMB1,351.2 billion. Pharmaceutical growth will likely remain positive but materially slower, encouraging providers to emphasize integrated care and service differentiation.
03Patient visits continue rising
High confidenceChina’s TCM medical institutions recorded 1.681864 billion visits in 2024, up from 1.535008 billion in 2023. A 2025 national health statistic cited by a local government release reports 1.85 billion TCM visits, an increase of 170 million year on year.[18]
Forecast 2027: Visits should continue expanding in 2027, likely at a high-single-digit rate as chronic-disease management, rehabilitation and preventive-care demand supports repeat use. Growth will be strongest in outpatient and community settings rather than inpatient care.
04Institution numbers keep expanding
High confidenceChina had 112,032 TCM medical and health institutions at the end of 2025, an increase of 8,328 from the previous year. The same release reports 1.236 million TCM health workers, up by 77,000 year on year.[18]
Forecast 2027: The provider base should expand again in 2027, led by outpatient clinics, community TCM facilities and private providers. Competition for qualified practitioners and high-volume locations is likely to intensify alongside capacity growth.
05Digital TCM services scale rapidly
High confidenceThe industry forecast identifies digitalization and improved service convenience as drivers of the ‘other’ TCM segment, which includes TCM diagnostic and health-monitoring devices. That segment is forecast to increase from RMB54.6 billion in 2024 to RMB162.1 billion in 2029, a 24.3% CAGR.[6]
Forecast 2027: In 2027, online consultations, remote follow-up, digital health records and TCM monitoring devices should become more common extensions of physical care. Digital services will likely grow faster than the core market, although clinical validation and data governance will constrain adoption in higher-risk applications.
06Preventive wellness demand broadens
Medium confidenceThe 2025–2029 market outlook describes a structural shift from a medicine-centered model toward integrated medical and wellness development. TCM medical services already represented the largest component of the cited market, at RMB1,001.6 billion in 2024.[6]
Forecast 2027: In 2027, preventive consultations, health management, sleep and stress services, rehabilitation and age-related wellness programs should capture a larger share of consumer spending. Providers will increasingly package clinical TCM with non-clinical wellness services, creating both growth opportunities and quality-control risks.
07Pharmaceutical growth remains moderate
High confidenceTCM pharmaceuticals grew from RMB361.3 billion in 2023 to RMB392.4 billion in 2024, while the industry forecast projects only a 4.1% CAGR from 2024 to 2029. The filing attributes earlier volatility partly to pandemic disruption and drug-pricing fluctuations.[6]
Forecast 2027: Pharmaceutical revenue should reach approximately RMB446.8 billion in 2027 under the cited forecast. Volume growth is likely to be offset partly by pricing discipline, procurement pressure and a shift in value creation toward services and differentiated products.
08Evidence requirements become stricter
High confidenceWHO’s September 2026 research agenda states that traditional, complementary and integrative medicine receives less than 1% of global health research funding despite being used by billions of people. The agenda prioritizes evidence generation for safety, effectiveness, regulation, service delivery and financing.[10]
Forecast 2027: In 2027, Chinese manufacturers and providers will face stronger pressure to produce clinical, real-world and safety evidence, especially for products seeking wider international acceptance. Research partnerships, standardized outcomes and data-enabled clinical studies should become more commercially important.
09Traditional-knowledge protection formalizes
High confidenceChina’s Regulation on the Protection of Traditional Chinese Medicine Traditional Knowledge was promulgated on October 23, 2026 and takes effect on January 1, 2027. It covers theories and methods, classic and proven formulas, cultivation and identification techniques, decoction-piece processing and traditional preparation methods.[12][19]
Forecast 2027: The regulation should make documentation, recognition, transmission and responsible commercialization of traditional knowledge more formal in 2027. It may support new product development while increasing compliance requirements around attribution, benefit sharing and unauthorized appropriation.
10Global policy integration advances
High confidenceWHO’s Global Traditional Medicine Strategy 2025–2034 focuses on strengthening evidence, appropriate regulation, health-system integration and cross-sector value. The strategy was adopted by the World Health Assembly in 2025, and WHO launched its accompanying global research agenda in September 2026.[10]
Forecast 2027: In 2027, international demand for standardized Chinese medicine services, training, research collaboration and regulated products should increase. The opportunity will be strongest in markets willing to integrate TCM into health systems, but market access will depend increasingly on local evidence and regulatory compliance.
04 Statistics
Market Intelligence
Market size and service revenue in the traditional chinese medicine industry
- RMB1,001.6 billion was the 2024 revenue of China’s TCM healthcare service industry, defined as revenue generated by TCM healthcare service providers.[1]
Growth forecasts for the traditional chinese medicine industry
- China’s TCM outpatient visits are projected to reach 3.3 billion in 2029, implying a 6.8% CAGR from 2024 to 2029.[1]
- China’s TCM healthcare service revenue is projected to reach RMB1,620.5 billion in 2029, implying a 9.9% CAGR for 2025–2029.[1]
- China’s TCM healthcare service market is projected to reach RMB1.9 trillion in 2029, implying a 10.2% CAGR from 2024 to 2029; the study defines market size as patient expenditures during diagnosis and treatment.[1]
05 Statistics
Pricing
Fees and price levels in the traditional chinese medicine industry
- HK$340–460 is the listed basic consultation fee, including three packs of Chinese medicines, at a Hong Kong registered Chinese medicine practitioner updated on 23 September 2026.[2]
- HK$400–550 is the listed fee for acupuncture at a Hong Kong registered Chinese medicine practitioner updated on 23 September 2026.[2]
- HK$120 per visit is the government-subsidised consultation fee at Hong Kong’s 18 Chinese Medicine Clinics cum Training and Research Centres, according to a 2023 government reply.[3]
06 Statistics
Risk & Compliance
Regulation and licensing in the traditional chinese medicine industry
- 3 consecutive years of apprenticeship are required for traditional-medicine apprenticeship assessment in China.[4]
- 3 years of registered practice is required for an individual establishing a Chinese medicine clinic in China, unless the person holds a Chinese medicine specialist-practitioner certificate.[4]
- 5 years of lawful traditional-medicine clinical practice is required to apply for the specialist-practitioner assessment in China.[4]
07 Statistics
Market Structure
Cross-border activity and trade in the traditional chinese medicine industry
- 542,000 overseas service visits were reported by Chinese traditional Chinese medicine service-trade pilot institutions in 2024, versus 391,000 domestic visits.[5]
- China had 31 traditional Chinese medicine service-export bases in 2024, comprising medical institutions, higher-education institutions and other service providers.[5]
- Overseas services represented approximately 27.6% of reported service revenue for Chinese traditional Chinese medicine service-trade pilot institutions in 2024.[5]
- 344 Chinese traditional Chinese medicine service-trade pilot institutions reported 933,000 service visits in 2024, including domestic and overseas services.[5]
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
Samuel Norberg. (2026, November 22). Traditional Chinese Medicine Industry Statistics. Gitnux. https://gitnux.org/traditional-chinese-medicine-industry-statistics
Samuel Norberg. "Traditional Chinese Medicine Industry Statistics." Gitnux, 22 Nov 2026, https://gitnux.org/traditional-chinese-medicine-industry-statistics.
Samuel Norberg. 2026. "Traditional Chinese Medicine Industry Statistics." Gitnux. https://gitnux.org/traditional-chinese-medicine-industry-statistics.
Sources & references
19 sources cited across this report